METTL3 and diabetic kidney disease: Furthermore, the specific deletion of METTL3 in podocytes showed no significant alterations in renal pathology, UACR and podocyte differentiation markers when compared to the wild‐type (WT) group, underscoring the specific protective effects of METTL3 deletion against podocyte injury in the context of DKD (Figure 2C–H).